The Prince Charles Hospital

A $17.8 million funding boost enables the University of Queensland to begin clinical trials of Hi1a, a spider venom-derived peptide, for treating heart attacks and protecting donor hearts. Hi1a has shown efficacy in animal models, potentially improving patient survival and expanding the donor heart pool.

A UQ-led project, funded by $17.8 million from MRFF, will move to human clinical trials to test Hi1a, a peptide from K'gari funnel web spider venom, as a treatment for heart attack and donor heart protection. If successful, it could improve survival rates, expand donor heart availability, and reduce healthcare costs.

Australian-made drug Hi1a, derived from K'gari funnel-web spider venom, aims to revolutionize heart attack and stroke treatment, protect donor hearts, and improve survival rates. Funded by $17.8 million from the Medical Research Future Fund, clinical trials are set to begin within the year.

IMB-led project to develop Hi1a, a peptide from K’gari funnel web spider venom, for treating heart attacks and protecting donor hearts, receives $17.8 million for human clinical trials. Hi1a showed efficacy in animal models, aiming to improve patient survival, expand donor heart pool, and reduce healthcare costs.